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The LKB1-salt-inducible kinase pathway functions
as a key gluconeogenic suppressor in the liver
Kashyap Patel1,*, Marc Foretz2,3,4,*, Allison Marion2,3,4, David G. Campbell1, Robert Gourlay1,
Nadia Boudaba2,3,4, Emilie Tournier2,3,4, Paul Titchenell5, Mark Peggie1, Maria Deak1, Min Wan5,
Klaus H. Kaestner5, Olga Go¨ransson6, Benoit Viollet2,3,4, Nathanael S. Gray7, Morris J. Birnbaum5,
Calum Sutherland8 & Kei Sakamoto1,w
LKB1 is a master kinase that regulates metabolism and growth through adenosine
monophosphate-activated protein kinase (AMPK) and 12 other closely related kinases. Liver-
specific ablation of LKB1 causes increased glucose production in hepatocytes in vitro and
hyperglycaemia in fasting mice in vivo. Here we report that the salt-inducible kinases (SIK1,
2 and 3), members of the AMPK-related kinase family, play a key role as gluconeogenic
suppressors downstream of LKB1 in the liver. The selective SIK inhibitor HG-9-91-01 promotes
dephosphorylation of transcriptional co-activators CRTC2/3 resulting in enhanced
gluconeogenic gene expression and glucose production in hepatocytes, an effect that is
abolished when an HG-9-91-01-insensitive mutant SIK is introduced or LKB1 is ablated.
Although SIK2 was proposed as a key regulator of insulin-mediated suppression of
gluconeogenesis, we provide genetic evidence that liver-specific ablation of SIK2 alone has no
effect on gluconeogenesis and insulin does not modulate SIK2 phosphorylation or activity.
Collectively, we demonstrate that the LKB1–SIK pathway functions as a key gluconeogenic
gatekeeper in the liver.
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B
lood glucose concentration is tightly controlled in healthy
humans to prevent the toxic effects of prolonged hyper-
glycaemia (diabetic complications) and the acute debilitat-
ing effects of hypoglycemia (coma). Two vital components to this
control are the suppression of hepatic glucose output following a
meal, and the induction of hepatic glucose production during
prolonged fasting. The latter involves increased breakdown of
stored hepatic glycogen and de novo synthesis of glucose from
substrates including glycerol, lactate and amino acids (gluconeo-
genesis), both in response to glucagon released from pancreatic
a-cells when blood glucose falls. In the postprandial state, these
processes are largely suppressed by insulin released from
pancreatic b-cells and the concomitant decrease in glucagon in
response to elevated blood glucose and glucose itself. Deregula-
tion of one or more of these processes contributes to development
of metabolic disorders such as type 2 diabetes. Therefore
delineating the molecular control of glucose homoeostasis is
fundamental to combating the rising tide of metabolic disease in
modern populations.
A key point of control of hepatic gluconeogenesis is
transcriptional regulation of genes encoding rate-controlling
enzymes, including the catalytic subunit of glucose-6-phosphatase
(G6Pase, encoded by the G6pc gene) and cytosolic phosphoe-
nolpyruvate carboxykinase (PEPCK, encoded by the Pck1 gene).
Two major signalling pathways that suppress gluconeogenic gene
transcription are the insulin signalling pathway and also
putatively the LKB1/adenosine monophosphate-activated protein
kinase (AMPK) pathway. Substantial evidence supports a model
in which insulin, via Akt-mediated phosphorylation and inhibi-
tion of forkhead box protein-O (FoxO), reduces the expression of
G6pc and Pck1 (ref. 1). AMPK is a key intracellular energy sensor
and regulator of multiple metabolic processes2. Zhou et al.3
demonstrated that metformin (the most widely prescribed drug
for glycaemic control in people with type 2 diabetes) stimulated
AMPK and this was associated with inhibition of glucose
production in rat primary hepatocytes. Therefore AMPK was
proposed as a potential regulator of hepatic gluconeogenesis.
More recently we tested directly whether the effect of metformin
on hepatic gluconeogenesis required AMPK by investigating
metformin action in a mouse model lacking both AMPKa1 and
a2 catalytic subunits in hepatocytes4. Importantly liver-specific
AMPKa1/a2-null mice were normoglycaemic in both fasted and
fed states, and an acute administration of metformin to the
AMPKa1/a2-knockout (KO) mice resulted in glucose lowering
equivalent to the wild-type (WT) control animals. Moreover,
primary hepatocytes lacking AMPK treated with metformin
displayed a robust inhibition of glucose production. In addition,
we found that the pharmacological AMPK activator, A-769662
(that directly activates AMPK independently of canonical
AMP-binding sites)5–7, had no effect on glucose production.
However, the less specific AMPK activator 5-aminoimidazole-4-
carboxamide-1-b-D-ribofuranoside (AICAR), an AMP mimetic
(AICA ribonucleotide, ZMP)8, profoundly inhibited glucose
production even in hepatocytes derived from AMPKa1/a2-null
mice4. These data implicate AMP per se but indicate that AMPK
is not required for suppression of hepatic glucose production in
response to metformin or feeding. Interestingly, there is now
evidence for mitochondrial inhibition (independent of AMPK)
influencing the action of the cyclic AMP (cAMP)-dependent
protein kinase (also known as protein kinase A (PKA)) signalling
pathway in the regulation of hepatic gluconeogenesis9,10.
Although loss of AMPK does not alter regulation of hepatic
gluconeogenesis, ablation of hepatic LKB1, a major upstream
kinase of AMPK, was associated with hyperglycaemia in mice11.
There was also a higher rate of basal/unstimulated and cAMP-
stimulated glucose production in LKB1 KO hepatocytes
compared with control cells4. LKB1 is a master kinase that
directly phosphorylates the activation loop of AMPKa1, a2 and
another 12 kinases related to AMPK (thus called AMPK-related
kinases), including the salt-inducible kinase isoforms (SIK1/2/3;
refs 12,13). As its name suggests, SIK was cloned from adrenal
glands of rats fed with a high-salt diet14. The activity of all three
SIK isoforms is regulated through phosphorylation of a conserved
threonine residue in the T-loop of the kinase domain, a
phosphorylation which is essential for catalytic activity12.
Interestingly, it has been reported that SIK2 activity can also be
modulated by phosphorylation outside of the T-loop/kinase
domain. Indeed these alternative phosphorylation sites were
proposed to be critical in controlling the gluconeogenic gene
programme (Pck1 and G6pc) by regulating phosphorylation of the
cAMP-response element-binding protein (CREB)-regulated
transcription co-activator-2 (CRTC2) by SIK2 (ref. 15). Dentin
et al.16 proposed that SIK2 is a key enzyme in the pathways that
switch off hepatic gluconeogenesis in response to feeding/insulin.
They reported that insulin activated SIK2 through induction of
Ser358 phosphorylation downstream of phosphoinositide 3-
kinase (PI3K)–Akt signalling. Activated SIK2 in turn stimulated
CRTC2 phosphorylation and cytosolic translocation, thereby
disrupting CRTC2/CREB-induced gluconeogenic gene transcrip-
tion. The mechanism by which phosphorylation of Ser358
promotes catalytic activity of SIK2 was not described. In
contrast, a recent study has demonstrated that in 3T3-L1 and
Figure 1 | Glucagon but not insulin promotes phosphorylation of SIK2. (a) Recombinant HA–SIK2 was expressed in primary mouse hepatocytes
(8–12-week-old male C57BL/6) using adenoviral transduction 16 h prior to stimulation with 0.1 mM glucagon or 10 nM insulin for 10min. HA–SIK2 was
immunoprecipitated from 5mg of lysates with HA-agarose beads and the precipitates were subjected to SDS–polyacrylamide gel electrophoresis followed
by colloidal coomassie staining. Bands corresponding to HA–SIK2 (boxed) were excised, in-gel digested with trypsin and analyzed using liquid
chromatography mass spectrometry (LC-MS) as described in Methods. (b) Table lists the sequences of the phosphopeptides identified, m/z values
and respective phosphorylated residues (p) of SIK2 in the glucagon-treated sample. (c) Primary hepatocytes were stimulated with either 0.1 mM glucagon
or 10 nM insulin for 10min prior to cell lysis. Endogenous SIK2 was immunoprecipitated from cell extracts and the resultant precipitates were
immunoblotted with the indicated antibodies. (d) Primary hepatocytes were isolated from Akt2þ /þ and liver-specific Akt2 / mice and then stimulated
with 10 nM insulin or 100mM Bt2-cAMP for 10min prior to cell lysis. The lysates were immunoblotted with the indicated antibodies. (e) Primary
hepatocytes were pre-treated with 2 mM MK-2206 for 1 h followed by 0.1 mM glucagon or 10 nM insulin treatment for 10min. The lysates were
immunoblotted with the indicated antibodies. Endogenous SIK2 was immunoprecipitated and was subjected to in vitro kinase assay as described in the
Methods. Data is presented as mean±s.d., n¼ 3. (f) Primary mouse hepatocytes were pre-treated with 25mM H-89 for 1 h followed by 0.1 mM glucagon
treatment for 10min prior to cell lysis. Lysates were immunoblotted with the indicated antibodies. (g) Liver extracts were generated from C57BL/6 male
mice (8–10-week-old) that had been subjected to ad libitum feeding, 16 h fasting or 16 h fasting followed by 4 h refeeding. Endogenous SIK2 was
immunoprecipitated from liver extracts and the precipitates were immunoblotted with the indicated antibodies or subjected to in vitro kinase assay. Data is
presented as mean±s.d., n¼ 3. (h) GFP alone, GFP–SIK2 wild-type (WT) or the indicated GFP–SIK2 mutants were expressed in primary hepatocytes using
adenoviral vectors (1:2 MOI) 16 h prior to 0.1mM glucagon treatment for 10min. The lysates were immunoblotted with the indicated antibodies. The
recombinant SIK2 3A protein included S343A, S358A and T484A mutations, while 4A mutant had these mutations plus the S587A mutation.
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rat primary adipocytes, agents that increase intracellular cAMP
levels promoted Ser358 phosphorylation on SIK2, without any
alteration of SIK2 catalytic activity measured in vitro17.
Importantly, in contrast to Dentin et al.16, they did not observe
induction of Ser358 phosphorylation on SIK2 in response to
insulin. Therefore the above studies have not reached a consensus
on how hormones such as insulin and glucagon regulate SIK2.
Clearly, hormones/agonists that stimulate cAMP/PKA and/or
PI3K–Akt in cells promote phosphorylation of SIK2 at multiple
sites; however, since the discrepancies described above suggest
Basala
c d g
e
h
b fGlucagon Insulin
250 kDa 
100 kDa 
HA-SIK2 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
150 kDa 
Peptide ID m/z
Site of
phosphorylation
on peptide
S(p)SFPVEQR 515.2 Ser343
690.8 Ser358
AQTVGLPVTMH(p)SPNMR
RP(p)STIAEQTVAK
909.2 Ser379
RH(p)TLSEVTNQLVVMPGAGK
RA(p)SDTSLTQGIVAFR
1059.0 Thr484
851.4 Ser587
VASP
Total SIK2
pSer473 Akt
GAPDH
pSer358 SIK2
Total Akt2
Akt2+/+ Akt2–/–
Ba
sa
l
In
su
lin
Ba
sa
l
In
su
lin
Bt
2-
cA
M
P
Bt
2-
cA
M
P
GAPDH
Total VASP
pThr308 Akt
Total Akt
pSer157 VASP
Total SIK2
pSer358 SIK2
MK-2206 2 μM
G
lu
ca
go
n
In
su
lin
Ba
sa
l
G
lu
ca
go
n
In
su
lin
Ba
sa
l
– + ++––
0 
1 
2 
3 
4 
SI
K2
 k
in
as
e
(ac
tiv
ity
 m
U 
mg
–
1 )
MW kDa
50
50
50
50
100
100
37
MW kDa
50
50
50
100
100
37
pSer343 SIK2
pPKA substrate
pAkt substrate
Total SIK2
Input
Total SIK2
GAPDH
Total VASP
pSer157 VASP
pThr308 Akt
IB:
IgG SIK2IP:
pSer358 SIK2
Total SIK2
pThr484 SIK2
Total SIK2
pThr175 SIK2
Total SIK2
Total SIK2
Total SIK2
pSer358 SIK2
G
lu
ca
go
n
In
su
lin
Ba
sa
l
G
lu
ca
go
n
In
su
lin
Ba
sa
l
Total Akt
MW kDa
100
100
100
100
100
100
100
100
100
100
100
50
50
50
50
37
100
100
100
Basal Glucagon
H-89 +– +– –+
CRTC2
pSer358 SIK2
Total SIK2
GAPDH
pSer1756 IP3R
Total IP3R
Fasted
16 h
Refed
4 h
IgG SIK2
pSer343 SIK2
Total SIK2
Tubulin
pThr308 Akt
Total Akt
pSer358 SIK2
pThr484 SIK2
Total SIK2
Total SIK2
Total SIK2
Input
IP:
IB:
0 
2 
4 
6 
8 
pThr389 p70S6K 
SI
K2
 k
in
as
e 
ac
tiv
ut
y
(m
U 
mg
–
1 )
Ad libitum
CRTC3
– + – + – + – + – + – +Glucagon
GFP WT S343A S358A T484A S587A
– + – + – +
T175A3A 4A
VASP
GFP(SIK2)
GAPDH
pSer246 HDAC4
CRTC2
100
100
100
100
100
100
100
50
75
75
250
250
50
50
50
100
100
MW kDa
MW kDa
MW kDa
37
100
75
37
75
150
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5535 ARTICLE
NATURE COMMUNICATIONS | 5:4535 |DOI: 10.1038/ncomms5535 |www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.
cell/tissue-specific aspects to the regulation of SIK2, it is
imperative to study these processes in precise detail in the liver,
the key site of abnormal gluconeogenesis in metabolic disease.
In the current study, we demonstrate that potent and selective
SIK inhibitors promote dephosphorylation of CRTC2/3, resulting
in increased gluconeogenic gene expression and glucose produc-
tion in mouse primary hepatocytes, which is abolished when the
drug/inhibitor-resistant mutant of SIK2 is introduced. Both the
SIK inhibitor and glucagon increase glucose production in LKB1
control hepatocytes, but only glucagon has the effect in LKB1 KO
hepatocytes. Although SIK2 was proposed as a key regulator for
insulin-mediated suppression of gluconeogenesis via phosphor-
ylation/activation, we provide genetic evidence that liver-specific
ablation of SIK2 alone has no effect on gluconeogenesis and
insulin does not modulate SIK2 phosphorylation/activity.
Together these data provide evidence that SIK isoforms play a
key role as ‘molecular gate-keepers’ for hepatic glucose produc-
tion by keeping the gluconeogenic programme repressed, and this
can be released by fasting/glucagon signals through a pathway at
least partially independent of SIKs.
Results
Glucagon but not insulin promotes phosphorylation of SIK2.
Recombinant haemagglutinin (HA)-tagged SIK2 was expressed in
mouse primary hepatocytes using adenovirus and the cells were
left untreated or treated with glucagon or insulin. HA–SIK2
protein was affinity-purified (Fig. 1a), in-gel digested with trypsin
and the resulting peptides were analyzed by liquid chromato-
graphy-tandem mass spectrometry (LC-MS-MS). We identified
several phospho-peptides in a precursor ion scanning LC-MS-MS
analysis that had markedly higher intensity in response to
glucagon treatment than basal or insulin treatment (Fig. 1b,
Supplementary Figs 1 and 2). Analysis of these phospho-peptides
identified Ser343, Ser358, Ser379, Thr484 and Ser587 as phos-
phorylation sites on SIK2 (Fig. 1b). The identification of Ser342/
343 was ambiguous from OrbiTrap data but data from the QTrap
analysis showed that Ser343 was phosphorylated (Supplementary
Fig. 1A). It should be noted that we have also identified Ser486
as a potential phosphosite (RHTL(p)SEVTNQLVVmPGAGK:
(m denoting oxidized Met (Supplementary Fig. 1E)) in the
phosphopeptide that contains Thr484. However, since Thr484,
but not Ser486, is highly predicted as a PKA site based on con-
sensus sequence and by Motifscan (http://scansite.mit.edu/), we
focused on the Thr484 site. Moreover, Ser379 is not conserved
between human (MHSPNMRLL) and mouse (LHPPNVRLM)
and was not further studied. The LC-MS-MS analysis coverage of
HA–SIK2 was B80% of the total sequence for all conditions
studied (Supplementary Fig. 3). To validate the mass spectro-
metry-based phospho-peptide mapping results, we generated or
obtained phospho-specific antibodies against four sites identified
in the glucagon-treated hepatocytes (Ser343, Ser358, Thr484 and
Ser587). The specificity of these antibodies was confirmed using
lysates from primary hepatocytes that had been adenovirally
transduced with constructs encoding WT GFP–SIK2 or the
cognate phosphorylation-defective GFP–SIK2 mutants (Ser/Thr
to Ala) (Supplementary Fig. 4). The effect of glucagon or insulin
on recombinant SIK2 phosphorylation in primary mouse hepa-
tocytes was then investigated using the characterized phospho-
specific antibodies. In parallel experiments, endogenous SIK2 was
immunoprecipitated from cell extracts, and then subjected to
immunoblot analysis with the phospho-specific antibodies
(Fig. 1c). In all experiments, insulin promoted Akt phosphor-
ylation, whereas glucagon increased phosphorylation of the PKA
substrate vasodilator-stimulated phosphoprotein (VASP), con-
firming efficacy of the hormonal treatment. Ser343, Ser358 and
Thr484 phosphorylation on both the endogenous SIK2 (Fig. 1c)
and adenovirally-overexpressed recombinant SIK2 proteins
(Supplementary Fig. 4) was robustly increased following glucagon
treatment of primary hepatocytes. In contrast, insulin had no
effect on phosphorylation of any of these sites on SIK2 (Fig. 1c).
Enhanced SIK2 phosphorylation was also detected with the
phospho–PKA and phospho–Akt substrate antibodies following
glucagon, but not following insulin treatment (Fig. 1c). Similar
results were obtained in HEK293 cells where forskolin, which
directly activates adenylate cyclase and stimulates cAMP pro-
duction hence activating PKA, promoted SIK2 phosphorylation
(both overexpressed and endogenous proteins) detected by site-
specific/phospho-specific SIK2 antibodies (Supplementary Figs 5
and 6) as well as phospho–PKA and phospho–Akt substrate
antibodies (Supplementary Fig. 5). Although we observed that
glucagon promoted SIK2 Ser587 phosphorylation when WT
GFP–SIK2 was overexpressed (Supplementary Fig. 4), we failed to
observe a consistent increase in Ser587 phosphorylation in
endogenous SIK2, following its immunoprecipitation in response
to glucagon in primary hepatocytes. It should be noted that
neither glucagon nor insulin treatment altered Thr175 phos-
phorylation in the activation T-loop (LKB1 site12) of SIK2 in
hepatocytes (Fig. 1c).
Previous work reported that SIK2 Ser358 phosphorylation (as
measured using a phospho–Akt substrate antibody) was increased
by insulin through the PI3K–Akt2-dependent pathway in mouse
liver tissue and primary hepatocytes, and that this was associated
with an increase in SIK2 catalytic activity measured in vitro16.
We used the SIK2 Ser358 phospho-specific antibody to analyze
SIK2 phosphorylation in control or Akt2-deficient primary
hepatocytes18 treated with insulin or a cell-permeable cAMP
analogue (Bt2-cAMP). SIK2 was phosphorylated on Ser358 in
response to Bt2-cAMP in both genotypes, but not in cells treated
with insulin (Fig. 1d). To further clarify if there is any potential
contribution of the PI3K–Akt pathway to the regulation of SIK2
Ser358 phosphorylation, immunoblot analysis was performed on
lysates from primary mouse hepatocytes incubated with an Akt
inhibitor (MK-2206) with or without hormones (Fig. 1e). As
anticipated, MK-2206 blocked insulin-stimulated phosphory-
lation of Akt, but it had no influence on SIK2 Ser358
phosphorylation induced by glucagon. Incubation of
hepatocytes with H-89, a selective PKA inhibitor, abolished the
phosphorylation of the known PKA substrate, inositol 1,4,5-
trisphosphate receptor (IP3R; ref. 19), CRTC2 dephosphorylation
and also SIK2 Ser358 phosphorylation, confirming that glucagon-
induced phosphorylation of Ser358 was most likely mediated
through the PKA pathway (Fig. 1f).
To determine if glucagon-induced phosphorylation of SIK2
had any impact on its catalytic activity, endogenous SIK2 was
immunoprecipitated from cells incubated with or without
hormones, and in vitro kinase assays performed. As shown in
Fig. 1e, SIK2 activity was unaltered by glucagon or insulin in the
presence or absence of MK-2206. This was further explored by
measuring the activity of recombinant SIK2 Ser/Thr to Ala
mutants. We observed that all single and combined SIK2 mutants
(3A; S343A/S358A/T484A or 4A; S343A/S358A/T484A/S587A)
displayed comparable activity irrespective of glucagon presence in
primary hepatocytes (Supplementary Fig. 7). To further validate
the data obtained using primary hepatocytes in a more
physiological context, immunoblot analysis of liver extracts
generated from mice following 16 h/overnight fasting or 16 h
fasting followed by 4 h refeeding was performed. Immunoblotting
of immunoprecipitated SIK2 from these liver extracts confirmed
that phosphorylation of Ser343, Ser358 and Thr484 increased
following fasting but not after refeeding (Fig. 1g). Consistent
with the cell-based data, immunoprecipitated SIK2 activity was
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the same when isolated from fasted or refed liver extracts
(Fig. 1g).
Taken all together, we provide compelling evidence that
cAMP/PKA-mediated signalling in response to fasting/glucagon
promotes hepatic SIK2 phosphorylation at multiple sites, but in
contrast there is no increase in phosphorylation of these sites with
feeding/insulin. In addition, glucagon-induced SIK2 phosphor-
ylation does not seem to influence SIK2 intrinsic catalytic activity
when isolated from hepatocytes/liver, and activity is measured
in vitro after immunoprecipitation. Since we cannot rule out the
possibility that glucagon-mediated phosphorylation of SIK2 may
modulate its downstream targets in intact cells without altering
intrinsic activity, we overexpressed single or multi-mutants
(3A or 4A) in mouse primary hepatocytes and assessed
phosphorylation of CRTC2/3 and histone deacetylase 4 (HDAC4,
another known SIK substrate). All the single mutants tested
showed no effect on glucagon-mediated dephosphorylation.
However interestingly, in SIK2 3A or 4A mutant-expressing cells
glucagon-induced dephosphorylation of CRTC2/3 and HDAC4
was prevented (Fig. 1h), which was associated with a modest
(B20%) inhibition of glucagon-induced glucose production
(Supplementary Fig. 8A). Although this indicates that glucagon-
mediated phosphorylation of SIK2 is capable of altering cellular
activity by as yet unknown mechanism (s), any interpretation
from overexpression studies needs to be taken with caution as
3A or 4A was overexpressed 410–20-fold above endogenous
SIK2 protein (data not shown). Overexpressed SIK2 WT and
3A/4A mutants were predominantly detected in the cytoplasm
WT SIK2 locus
a
b
c d g
f
e
Targeted SIK2 allele
Floxed SIK2 allele
Knockout SIK2 allele
1 2 3 4
1
FLP recombinase
CRE recombinase
LoxP site FLP site
2 3 4 Hygro
1 2 3 4
1 2 3 4
5 6 7
5 6 7
5 6 7
6 7
16
16
16
16
Thr175
400
300
Bl
oo
d 
gl
uc
os
e 
(m
g d
l–1
)
200
100
0
0 20 40
Time (min)
1.4
Heart
100 KDa
35 KDa
BATWATMuscleLiver
SIK2
GAPDH
WT WT Lo
x
CR
E
WT Lo
x
CR
E
WT Lo
x
CR
E
WT Lo
x
CR
ELox CRE
Ppargc1a
1.2
1.0
0.8
0.6
0.4
0.2
0
Fa
ste
d
Re
fed
Fa
ste
d
Re
fed
Fa
ste
d
Re
fed
Fa
ste
d
Re
fed
FastedFed
00
1
2
3
4
5
50
Bl
oo
d 
gl
uc
os
e 
(m
g d
l–1
)
SI
K 
ac
tiv
ity
 (m
U 
mg
–
1 )
SIK1 SIK2 SIK3
100
150
200
Refed
R
el
at
iv
e
m
R
N
A 
le
ve
ls
Pck1 Srebp-1c Fasn
1.2
1.0
0.8
0.6
0.4
0.2
0
2
4
6
8
10
12
14
0
10
20
30
40
50
60
70
0
Liver
SIK2 KO
Liver
SIK2 KO
100 KDa
70 KDa
35 KDa
Control
SIK2
PEPCK
GAPDH
Control
Fasted Refed
Control
Liver SIK2 KO
60 80 100 120
Figure 2 | Liver-specific SIK2-knockout mice display normal glycaemia. (a) Diagram of the generation of liver-specific SIK2-knockout (liver SIK2 KO)
mice. Exon 5 was flanked by loxP sites and a hygromycin resistance cassette flanked by FRT sites was inserted upstream from the 50 loxP site. The
hygromycin resistance cassette was excised by the expression of the FLP recombinase in vivo. Liver disruption of exon 5 flanked by loxP sites was achieved
by crossing SIK2-floxed mice with Alfp–Cre transgenic mice. (b) Immunoblotting of SIK2 in liver, vastus lateralis muscle, inguinal white adipose tissue
(WAT), brown adipose tissue (BAT) and heart from WT, SIK2-floxed (Lox) and liver SIK2-deficient (CRE) mice, demonstrating that the deletion was
effective and liver specific. (c) Kinase activity of SIK1, 2 and 3 in liver extracts generated from randomly fed control (white bars) and liver SIK2-KO (black
bars) mice. SIK1, 2 and 3 were immunoprecipitated with respective isoform-specific antibodies from liver extracts in triplicate and subjected to in vitro
kinase assay. Data is presented as mean±s.d., n¼ 3. (d) Blood glucose levels of control (white bars) and liver SIK2-KO (black bars) male mice (10-week-
old) fed ad libitum (fed), fasted for 18 h (fasted) or refed overnight with a high-carbohydrate diet following a 24 h fast (refed). n¼6–12 for each group.
(e) Evaluation of blood glucose levels during an oral glucose tolerance test (3 g kg 1) in control and liver SIK2-KO mice (n¼ 6 for each group). Values
are presented as mean±s.e.m. (f) Relative Ppargc1a, Pck1, Srebp-1c and Fasn mRNA levels measured by quantitative reverse transcription–PCR in the liver
of control (white bars) and liver SIK2-KO (black bars) mice fasted for 18 h or refed overnight with a high-carbohydrate diet following an 24h fast (refed).
n¼ 6 for each group. All values are presented as mean±s.e.m. (g) Immunoblotting of SIK2, PEPCK and GAPDH in the liver of control and liver SIK2-KO
mice fasted for 18 h or refed overnight with a high-carbohydrate diet following an 24 h fast (refed). Data are representative of nine mice per group.
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(Supplementary Fig. 8B), but a relatively small amount of SIK2
may be localized in the nucleus, although this could not
be precisely and quantitatively assessed. Moreover, CRTC2
localization was not altered when SIK2 3A/4A mutants were
introduced (data not shown).
SIK2 is dispensable for the regulation of hepatic gluconeo-
genesis. To address whether SIK2 is necessary and plays a key
role in hepatic gluconeogenesis, a liver-specific SIK2-KO mouse
model was generated by Cre-LoxP recombination (Fig. 2a).
SIK2fl/flCre / (control) and liver-specific SIK2fl/flCreþ /
(KO) mice are indistinguishable from SIK2þ /þ (WT) mice,
displaying normal growth and no overt phenotype. Immunoblot
analysis showed that SIK2 protein expression (in all tissues ana-
lyzed including liver) was comparable between the SIK2þ /þ and
SIK2fl/flCre / mice, while a profound liver-specific depletion of
SIK2 protein was observed in SIK2fl/flCreþ / mice (Fig. 2b).
There were no compensatory changes in SIK1 and SIK3 activity
in SIK2-deficient liver (Fig. 2c).
We next examined the impact of hepatic SIK2 deficiency on
blood glucose homeostasis. Liver-specific SIK2-KO mice exhib-
ited normal blood glucose levels in randomly fed, 18-h-fasted and
refed animals (Fig. 2d). Hepatic SIK2-KO mice displayed a
similar blood glucose profile to control mice throughout a glucose
tolerance test (Fig. 2e). Expression of key hepatic gluconeogenic
and lipogenic genes was assessed in 18-h-fasted and refed
animals. We observed that hepatic SIK2 deficiency had no
influence on fasting- or feeding-mediated changes in the gene
expression of Pck1, Ppargc1a or Srebp-1c, as well as Fasn (Fig. 2f).
This was further validated by immunoblot for PEPCK protein
(Fig. 2g).
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We confirmed this in vivo data by examining the effect of SIK2
deficiency on gluconeogenesis in primary hepatocytes. We first
assessed cAMP–PKA-mediated changes in CRTC2 dephosphor-
ylation and gluconeogenic gene expression in control and SIK2-
KO hepatocytes. Treatment of hepatocytes with Bt2-cAMP caused
a robust downward gel-shift/dephosphorylation of CRTC2
(Fig. 3a), and increases in messenger RNA (mRNA) expression
of Ppargc1a, Pck1 and G6pc, with no difference between control
and SIK2-KO hepatocytes (Fig. 3b). In addition, induction of
PEPCK protein expression was comparable between control and
SIK2-KO hepatocytes (Fig. 3a). Consistent with these results and
also with data from in vivo experiments (Fig. 2d,f and g), basal
and Bt2-cAMP-stimulated glucose production (4–24 h) in pri-
mary hepatocytes was not altered by genetic deletion of SIK2
(Fig. 3c).
Given that SIK2 and AMPK are able to phosphorylate CRTC2
on a common site (Ser171; refs 11,20,21), we wanted to check if
AMPK might compensate for the lack of SIK2 and vice versa. For
this purpose, we generated mice lacking SIK2, AMPKa1 and
AMPKa2 simultaneously and specifically in the liver. Triple
deletion of hepatic AMPKa1/a2 and SIK2 did not affect blood
glucose levels in randomly fed, 18-h-fasted and refed mice
(Fig. 4a). Furthermore, expression of key hepatic gluconeogenic
(Ppargc1a, Pck1) and lipogenic (Srebp-1c, Fasn) and hepatic
PEPCK protein levels were similar between control and triple KO
(TKO) mice (Fig. 4b,c). Consistent with these observations, basal
and Bt2-cAMP- or glucagon-induced glucose production were
comparable between control and the triple AMPKa1/a2/
SIK2-deficient hepatocytes (Fig. 5a). CRTC2 gel mobility in
unstimulated or stimulated (Bt2-AMP or glucagon) conditions
was comparable between the triple AMPKa1/a2/SIK2-deficient
and control hepatocytes (Fig. 5b). In contrast, phosphorylation of
CRTC2 and acetyl-CoA carboxylase (ACC) in response to
metformin was blunted in TKO hepatocytes (Fig. 5c) as
previously observed in AMPK-deficient hepatocytes4. Gluconeo-
genic gene (Ppargc1a, Pck1 and G6pc) expression was comparable
between control and the TKO hepatocytes in unstimulated or
stimulated (Bt2-AMP or glucagon) conditions (Fig. 5d).
These results highlight that deletion of AMPK or SIK2, alone
or in combination, are not sufficient to mimic the alteration in
the regulation of gluconeogenesis (Figs 2–5) observed in LKB1-
deficient liver and hepatocytes4,11.
Inhibition of SIKs promotes glucose production in primary
hepatocytes. The previously described experiments suggest that
SIK2 is dispensable for control of hepatic gluconeogenesis,
perhaps because loss of SIK2 can be compensated by other SIK
isoforms (but not by AMPK). To fully delineate the role of SIKs
in hepatic gluconeogenesis, it would be necessary to ablate the
activity of all SIK isoforms in the liver. We took advantage of
recently identified pan-SIK inhibitors whose potency and speci-
ficity have been well-characterized in vitro and in intact cells
(macrophages)22. Of note, they are specific to SIK isoforms and
require 4100-fold concentration to inhibit AMPK and other
AMPK-related kinases and LKB1 in cell-free assays22.
We first performed a dose-response (0.1–4 mM) and time-
course (4–12 h) study to determine the concentration of SIK
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inhibitor (HG-9-91-01) that is required for a robust and sufficient
suppression of SIK activity in mouse primary hepatocytes. We
confirmed that 4 mM is the saturating concentration required for
promoting CRTC2 dephosphorylation and glucose production in
mouse primary hepatocytes (data not shown). We assessed SIK
activity by monitoring the phosphorylation state of CRTC2 as
indicated by band-mobility shift and observed that HG-9-91-01
caused a dose-dependent increase in a faster migrating form of
CRTC2 (dephosphorylation) with a reciprocal reduction in the
slower migrating phosphorylated form (Fig. 6a). CRTC2 depho-
sphorylation in primary hepatocytes was more pronounced
following exposure to 4 mM HG-9-91-01 than that generated by
0.1 mM glucagon treatment.
It has been reported that in unstimulated hepatocytes, CRTC2
is highly phosphorylated and mostly localized in the cytoplasm.
Upon treatment with glucagon or stimuli that induce cellular
cAMP elevation, CRTC2 is dephosphorylated and translocates
into the nucleus11,21. Therefore, we used immunofluorescence
to examine if HG-9-91-01-induced dephosphorylation of
endogenous CRTC2 leads to its nuclear enrichment. As
previously reported, we found that CRTC2 is predominantly
localized in the cytoplasm of unstimulated cells. HG-9-91-01
treatment caused marked enrichment of CRTC2 in the nucleus,
comparable to the translocation in response to glucagon (Fig. 6b).
We next examined the effects of HG-9-91-01 on hepatic
gluconeogenesis by measuring gluconeogenic gene expression and
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glucose production. HG-9-91-01 treatment dose dependently
increased mRNA expression of Pck1 and G6pc and that effect was
similar in cells treated with 4 mM HG-9-91-01 or 0.1 mM glucagon
(Fig. 6c). Consistent with this observation, there was also a dose-
dependent increase in glucose production following HG-9-91-01
treatment (Fig. 6d). The structurally related SIK inhibitor KIN112
(10 mM; ref. 22) modestly, but significantly, increased glucose
production, CRTC2 and CRTC3 dephosphorylation and PEPCK
protein expression in mouse primary hepatocytes (Supplementary
Fig. 9).
Given the observation that glucagon and HG-9-91-01 both
promoted CRTC2 dephosphorylation, gluconeogenic gene
expression and glucose production in primary hepatocytes, we
hypothesized that glucagon-induced gluconeogenesis is at least in
part SIK dependent. Thus, we speculated that combined
treatment (HG-9-91-01 and glucagon) would not display an
additive increase in glucose production compared with individual
treatments. Contrary to our hypothesis, there was a significant
additive increase in glucose production when the two agents were
given to hepatocytes simultaneously (Fig. 6e), which was
accompanied by more pronounced dephosphorylation of
CRTC2 and HDAC4 than following individual treatments
(Fig. 6f).
The possible mechanism behind this additive effect was
investigated by measuring the phosphorylation of glucagon-
regulated signalling molecules proposed to be involved in
hepatic gluconeogenesis. In line with the observations shown in
previous studies, glucagon-induced phosphorylation of CREB,
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (PFKFB1)
and IP3R (Fig. 6f), which are known PKA substrates recently
implicated in the control of hepatic gluconeogenesis10,19,23. In
contrast, HG-9-91-01 had no effect on the phosphorylation of
these proteins. Combined treatment with HG-9-91-01 and
glucagon did not further enhance phosphorylation of these
proteins (CREB, PFKFB1 and IP3R) compared with glucagon
alone. However, it did have an additive effect on the
dephosphorylation of CRTC2 (Fig. 6f), which could explain the
additive effect on glucose production.
HG-9-91-01-induced glucose production is dependent on
LKB1 but not AMPK. LKB1-dependent kinases, including
AMPK and SIKs13, are reported to phosphorylate CRTC2 and
class IIa HDACs, and thus proposed to regulate hepatic
gluconeogenesis20,24. Despite the high homology of the kinase
domain between AMPK and SIKs, HG-9-91-01 has more than a
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Figure 6 | The SIK inhibitor HG-9-91-01 increases hepatic gluconeogenesis. (a) Primary hepatocytes (8–12-week-old male C57BL/6) were treated with
the indicated concentrations of HG-9-91-01 for 4, 8 or 12 h prior to cell lysis. Lysates were subjected to immunoblotting with the indicated antibodies.
Primary hepatocytes were also treated with 0.1mM glucagon for 12 h and included in the experiment as a positive control. (b) Primary hepatocytes
were treated with 4mMHG-9-91-01 for 1 h and 0.1 mM glucagon for 10min. Subsequently cells were fixed with 3.7% paraformaldehyde and immunostained
using a CRTC2 antibody and stained with 40,6-diamidino-2-phenylindole (DAPI) for nuclear visualization. Images were captured with a fluorescence
microscope (Nikon Eclipse Ti) using Nikon NIS-Elements BR 3.1 software. Scale bar is 10mm in length. (c) Relative mRNA levels of Pck1 and G6pc were
measured from primary hepatocytes using quantitative reverse transcription–PCR after an 8 h treatment with the indicated amount of HG-9-91-01 or
0.1mM glucagon. The mRNA levels were presented as fold increase from non-treated hepatocytes (basal) and are presented as mean±s.d., n¼ 3. *Po0.01
basal versus each treatment for Pck1 mRNA, # Po0.01 basal versus each treatment for G6pc mRNA. (d) Cell culture medium (12 h treatment) from the
same experiment (c) was used to analyze glucose production. Glucose production was normalized to total cellular protein content and presented as
percentage of glucose production by hepatocytes without treatment (basal). Glucagon treatment (0.1 mM) for 12 h was used as a positive control. Data is
presented as mean±s.d., n¼6. *Po0.01 basal versus 1mM HG-9-91-01, 4 mM HG-9-91-01 or glucagon. (e) Glucose production was measured from
primary hepatocytes that were treated with 4mM HG-9-91-01 and/or 0.1 mM glucagon for 8 h. Glucose production was normalized to total protein content
and presented as percentage of glucose production by hepatocytes without treatment (basal). Data is presented as mean±s.d., n¼ 6. *Po0.01 basal
versus HG-9-91-01 or glucagon, #Po0.05 HG-9-91-01 or glucagon versus HG-9-91-01 plus glucagon. (f) Primary hepatocytes were treated with 4mM
HG-9-91-01 for 8 h and/or 0.1 mM glucagon prior to cell lysis. Lysates were immunoblotted with the indicated antibodies.
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100-fold greater potency against SIKs than AMPK in a cell-free
assay22. However, the effect of HG-9-91-01 on AMPK in intact
cells has not been examined. Therefore it remained plausible that
at least part of the effect of this compound on hepatic
gluconeogenesis could be mediated through AMPK. To this
end, the effects of HG-9-91-01 on hepatic gluconeogenesis were
investigated in primary hepatocytes lacking both AMPKa
catalytic isoforms (a1/a2; ref. 4). Both control and AMPKa1/a2
KO hepatocytes showed similar basal as well as HG-9-91-01-
induced CRTC2 dephosphorylation and glucose production
(Fig. 7a). These results suggested that the ability of HG-9-91-01
to promote hepatic glucose production does not involve AMPK.
Catalytic activity of SIK requires LKB1-dependent T-loop
phosphorylation and thus SIK activity in LKB1-deficient HeLa
cells and mouse embryonic fibroblasts is profoundly reduced12.
We next examined the effect of HG-9-91-01 on glucose
homeostasis in mouse primary hepatocytes, isolated from a
liver-specific LKB1 KO mouse, to establish the dependency for
LKB1-induced SIK activity. Deletion of LKB1 was confirmed by
immunoblotting of liver tissue extracts derived from LKB1 KO
compared with control animals (Fig. 7b). LKB1 protein
expression was nearly ablated and T-loop phosphorylation of
AMPKa was robustly reduced in LKB1-deficient liver as shown
previously4.
SIK2 T-loop phosphorylation and activity were assessed after
immunoprecipitation by immunoblotting and in vitro kinase
assay, respectively. We observed that SIK2 protein expression was
comparable between control and LKB1-deficient liver, while
T-loop (Thr175) phosphorylation was undetectable in liver
extracts derived from liver LKB1 KO mice (Fig. 7b). Consistent
with this observation, SIK2 activity was profoundly reduced in
LKB1 KO liver. Residual expression of LKB1 and SIK2 activity
detected in LKB1-deficient liver could be due to non-hepatic cells (for
example, Kupffer cells and fibroblasts) present in whole liver tissue.
Next, we tested the response of primary hepatocytes isolated
from control and liver LKB1 KO mice to either HG-9-91-01 or
Bt2-cAMP. As described in our previous work4, we observed that
there was much lower phosphorylation of CRTC2 in LKB1-
deficient hepatocytes compared with control, in unstimulated
cells, which was associated with a significantly higher glucose
production in LKB1-deficient hepatocytes (Fig. 7c). In control
hepatocytes HG-9-91-01 treatment again caused a robust
downward band shift of total CRTC2 and a significant increase
in glucose production. In contrast, HG-9-91-01 resulted in only a
modest increase in band shift with no increase in glucose
production in LKB1 KO hepatocytes (Fig. 7c). These data indicate
a key functional role for the LKB1–SIK system as a ‘repressor’ of
hepatic gluconeogenesis. Interestingly, Bt2-cAMP was able to
promote a further band shift of CRTC2, and significantly
stimulate glucose production in these cells.
A drug-resistant SIK2 mutant abolishes HG-9-91-01-induced
gluconeogenesis. A powerful approach to establish the observed
effect of a compound, that inhibits a kinase of interest is not an
‘off-target’ effect, is to demonstrate that the inhibitor action is lost
when a drug-resistant mutant kinase is expressed in place of the
WT kinase. Clark et al.22 recently reported that the mutation of
the gatekeeper (a particular amino acid located towards the back
of the ATP pocket, which is a crucial determinant of kinase
inhibitor selectivity) threonine (SIK1 Thr103, SIK2 Thr96 and
SIK3 Thr146) to glutamine made SIK isoforms 100–1000-fold less
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Figure 7 | Effect of HG-9-91-01 in AMPK- or LKB1-knockout primary hepatocytes. (a) Primary hepatocytes from control (AMPKa1lox/loxa2lox/lox)
and liver-specific AMPKa1/a2 knockout (AMPK KO) male mice (10-week-old) were treated with the indicated amount of HG-9-91-01 for 8 h prior to cell
lysis. Immunoblot analysis was conducted with the indicated antibodies and glucose was measured in the culture medium. Glucose production was
normalized to total protein content and presented as percentage of glucose production by non-treated hepatocytes. Data is presented as mean±s.d., n¼ 3.
*Po0.01 basal versus 1mM HG-9-91-01 treatment in both genotypes and #Po0.001 basal versus 4mM HG-9-91-01 treatment in both genotypes.
(b) Endogenous SIK2 was immunoprecipitated from 1mg liver extracts of control (LKB1lox/lox) or liver-specific LKB1 knockout (LKB1 KO) mice using SIK2
antibody or pre-immune immunoglobulin G (IgG) and subjected to either in vitro kinase assay or immunoblot analysis. Pre-immune IgG was used as
negative control. Data is presented as mean±s.d., n¼ 3. Same liver extracts (40mg) were included in immunoblot analysis as input. (c) Glucose production
from primary hepatocytes of control (LKB1lox/lox) or liver-specific LKB1 knockout (LKB1 KO) mice was measured following 4 mM HG-9-91-01 or 100mM
Bt2-cAMP treatment for 8 h. Lysates from the same experiment were immunoblotted with the indicated antibodies. Data is presented as mean±s.d.,
n¼ 3. *Po0.01 basal versus each treatment in control and basal versus Bt2-cAMP in LKB1 KO, #Po0.01 basal control versus basal LKB1 KO, Bt2-cAMP
control versus Bt2-cAMP LKB1 KO.
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sensitive to HG-9-91-01 in vitro and the mutant proteins are
resistant to HG-9-91-01 when overexpressed in HEK293 cells
(Supplementary Fig. 10). Since SIK2 is relatively highly expressed
in the liver, the SIK2 drug-resistant mutant (T96Q) was
introduced in hepatocytes using an adenoviral expression
construct, and its expression and function were studied in
comparison with WT SIK2 (Fig. 8a). Importantly, expression and
kinase activity as well as T-loop phosphorylation (Thr175)
were similar between WT and the drug-resistant mutant of
SIK2 (Fig. 8a). As anticipated, glucagon caused comparable
phosphorylation of PKA substrates (IP3R and VASP) in all
conditions and induced SIK2 phosphorylation on Ser343, Ser358
and Thr484 in a similar manner in SIK2 WT- and drug-resistant
mutant-expressing cells (Fig. 8b).
We then sought to determine if expression of the drug-resistant
SIK2 mutant would abolish the downstream effects of
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immunoblotted with the indicated antibodies. (b) Primary hepatocytes were transduced for 24 h (1:5 MOI) with HA–SIK2 wild-type (Ad-SIK2 WT),
HA–SIK2 T96Q drug-resistant mutant (Ad-SIK2 DR) or Ad-GFP (as infection control) adenoviruses prior to cell lysis. The cells were treated for the last 12 h
with 1 or 4mM HG-9-91-01 or 0.1mM glucagon and lysates were subjected to immunoblotting with the indicated antibodies. (c) Primary hepatocytes were
infected (1:2 MOI) with HA–SIK2 adenovirus (Ad-SIK2) WT or DR mutant for 16 h followed by 4mM HG-9-91-01 treatment for 1 h before fixing the cells.
The cells were immunostained with the indicated antibodies. 40,6-diamidino-2-phenylindole (DAPI) was used for nuclear staining. Images were captured
with a fluorescence microscope (Nikon Eclipse Ti) using Nikon NIS-Elements BR 3.1 software. Scale bar is 10mm in length. (d) Gluconeogenic gene
expression was measured by quantitative reverse transcription–PCR in primary hepatocytes under the same conditions as in b other than glucagon
treatment. (e) The cell culture medium from the experiment in b was used to measure glucose production. Glucose production was normalized to total
protein content and presented relative to hepatocytes without treatment (basal). Data is presented as mean±s.d., n¼ 6. *Po0.01 basal versus each
treatment in Ad-GFP and in Ad-SIK2 WTgroup, basal versus glucagon in Ad-SIK2 DR group. $Po0.01 HG-9-91-01 treatment in SIK2 WT versus SIK2 DR
and #Po0.05 basal versus HG-9-91-01 treatment in Ad-SIK2 DR.
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HG-9-91-01 and glucagon in hepatocytes. We infected mouse
primary hepatocytes with an adenovirus encoding WT HA–SIK2,
drug-resistant HA–SIK2 mutant (T96Q) or GFP alone (control)
and the cells were then left untreated, treated with HG-9-91-01
(1 or 4mM) or with glucagon (0.1 mM) (Fig. 8b). In untreated
hepatocytes, expression of SIK2 WT and drug-resistant mutant
was similar and both conditions caused modestly higher
phosphorylation of CRTC2/3 compared with the GFP control.
Consistent with the previous experiments (for example, Fig. 6a),
HG-9-91-01 treatment promoted a robust dephosphorylation of
both CRTC2 and CRTC3 in control GFP-expressing cells and
also WT SIK2-expressing cells. The dephosphorylation of
CRTC2/3 was abrogated following HG-9-91-01 treatment of the
cells expressing the drug-resistant SIK2 mutant (Fig. 8b).
Strikingly HG-9-91-01-induced nuclear enrichment of CRTC2
was abolished in drug-resistant mutant-expressing hepatocytes
(Fig. 8c). Wild-type and drug-resistant mutant SIK2 both
appeared to localize in the cytosol and remained unaltered by
HG-9-91-01 treatment in hepatocytes. HG-9-91-01-stimulated
glucose production and induction of PEPCK protein expression,
as well as mRNA expression of Pck1 and G6pc was observed in
control GFP- and WT SIK2-expressing cells but all actions were
lost in the hepatocytes expressing the drug-resistant SIK2 mutant
(Fig. 8b,d,e), demonstrating that SIK2 mediates these actions of
the drug.
Discussion
Previous work by Dentin et al.16 reported that SIK2 plays an
important role in the control of insulin/feeding-mediated
suppression of hepatic gluconeogenesis through phosphorylation/
activation of SIK2 downstream of the PI3K–Akt signalling
pathway. In sharp contrast to this mechanism proposed by
Dentin et al.16, here we provide compelling opposing evidence
that insulin does not promote phosphorylation and activation of
SIK2 in the liver, and go on to show that liver-specific ablation of
SIK2 alone has no impact on fasting- and feeding-mediated
changes in gluconeogenic gene expression and blood glucose
levels in vivo.
We believe that the identification of Ser358 as a potential Akt
phosphorylation site in SIK2 in the previous work16 was indirect
and not robust. For example, it was initially identified based only
on the fact that the sequence around Ser358 conforms to the
minimum kinase consensus motif for Akt phosphorylation, and
the evidence that phosphorylation of endogenous SIK2 at Ser358
actually occurs in cells exposed to insulin was supported only by
the use of a generic phospho–Akt substrate-motif antibody16.
Work in cell-free assays and experiments with recombinant
WT and a S358A mutant of SIK2 expressed in HEK293 cells
provided evidence that Akt could phosphorylate wild type, but
not S358A SIK2.
The key finding that insulin promoted SIK2 phosphorylation
detected by the phospho–Akt substrate antibody16 was not
reproduced in our previous17 or current work, despite performing
multiple experiments in various cell systems (hepatocytes,
adipocytes and HEK293 cells (Supplementary Figs 5 and 6)).
Most importantly, our SIK2 phosphorylation analyses using
either unbiased mass spectrometry or site-specific phospho-
antibodies (as well as the phospho–Akt/PKA substrate-motif
antibodies), found no evidence that Ser358 phosphorylation was
induced by insulin/feeding, yet both approaches were able to
identify this as a major modification induced by glucagon/fasting.
It is worth noting that we confirmed that the phospho–Akt
substrate-motif (Arg–Xaa–Arg–Xaa–Xaa–pSer/Thr, Xaa, any
amino acid) and the phospho–PKA substrate-motif (Arg–Arg–
Xaa–pSer/T) antibodies both detect multiple phosphorylation
sites on SIK2 due to their overlapping epitopes. To eliminate
glucagon-induced phosphorylation detected using these
antibodies we had to simultaneously mutate three (3A; Ser343,
Ser358 and Thr484) or four (3A and Ser587) sites on SIK2
(Supplementary Fig. 4). This seriously questions their utility in
precise phosphorylation-site mapping experiments.
In line with what we previously demonstrated in adipocytes
treated with cAMP-inducing agents17, we found that SIK2
becomes phosphorylated at multiple sites in response to
glucagon/fasting, although the T-loop site that is
phosphorylated by LKB1 remains unchanged. Importantly, the
intrinsic activity of SIK2, isolated from liver cell/tissue extracts
and assayed in vitro, was not different in samples following
fasting/glucagon to that measured from fed/insulin-treated or
untreated tissue/cells. Consistent with this, mutations of any or all
(4A; four Ser/Thr residues to Ala) of the glucagon-induced
phosphorylation sites had no effect on SIK2 activity and did not
alter phosphorylation in the activation T-loop Thr175 site
(Supplementary Fig. 7). These results are in line with what we
previously demonstrated in adipocytes, and suggest that
phosphorylation of Ser343, Ser358, Thr484 and Ser587
(individually or all together) does not in itself modulate
intrinsic kinase activity. Instead, it appears that phosphorylation
of Thr175 by LKB1 maintains constant SIK2 intrinsic kinase
activity in hepatocytes, irrespective of the presence of hormones.
However, we cannot rule out the possibility that isolation of SIK2
by immunoprecipitation separates the kinase from a co-factor (s)
or interacting protein(s) that modulate activity of SIK2, and the
in vitro kinase assay may not truly reflect the in vivo/cellular
activity status of SIK2. Given that cAMP/PKA-mediated
phosphorylation promotes binding to 14-3-3 adaptor proteins17,
it is possible that glucagon-mediated phosphorylation of SIK2
alters its cellular localization and/or protein-protein interactions
and consequently modulates signalling. One interesting
observation was that when we overexpressed individual or
combination (3A or 4A) SIK2 mutants in mouse primary
hepatocytes, 3A- or 4A-SIK2-expressing cells did not display
glucagon-mediated dephosphorylation of CRTC2/3. This possibly
indicates that glucagon-mediated phosphorylation plays an
‘inhibitory role’ on SIK activity in vivo. However, this has to be
cautiously interpreted as the 3A or 4A mutants were
overexpressed 410–20-fold above endogenous SIK2 protein
and thus may have acted as dominant negative molecules.
Monitoring cellular SIK activity in response to glucagon is
challenging one approach would be to generate a fluorescent
reporter25 containing a SIK-targeting sequence and measure
kinetic changes in de novo SIK activity in response to glucagon in
hepatocytes.
Nonetheless, collectively the current results do not support the
proposed model that insulin-mediated suppression of hepatic
gluconeogenesis involves phosphorylation and activation of
SIK2. It can be noted that the same group that published the
insulin–Akt regulation of SIK2 (ref. 16) recently proposed a new
hypothesis/pathway that insulin/feeding switches off hepatic
gluconeogenesis through Akt-mediated phosphorylation of
IP3R (Ser2682). IP3R phosphorylation promotes CRTC2
phosphorylation and inhibition of gluconeogenic gene
expression19, providing an alternative SIK2-independent
pathway from the insulin receptor to reduced gluconeogenesis.
Indeed, there are multiple pathways known to turn off
gluconeogenesis by insulin including Akt2-dependent regulation
of FoxO1 and redirection of G6P to glycogen1,18.
In the current study, we used pan-SIK inhibitors together with
an inhibitor-resistant SIK mutant to reveal that acute and
selective pharmacological inhibition of SIK (s) significantly
increases hepatic gluconeogenesis in primary hepatocytes. On
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the other hand, we also provided genetic evidence that ablation of
SIK2 in the liver does not affect hormone-mediated changes in
gluconeogenesis and we confirmed that there were no compen-
satory changes in the activity of other SIK isoforms (SIK1/3) in
SIK2-deficient liver. These results suggest that SIK2 has no
significant role in the control of hepatic gluconeogenesis, or
alternatively, there is a degree of redundancy among the SIK
isoforms that does not require upregulation of SIK protein. To
test these hypotheses we performed short hairpin RNA
interference -mediated knockdown of the SIK isoforms (singly
and in combination) using adenovirus infection of SIK2-null
mouse primary hepatocytes. However, we could achieve only
B80% knockdown of SIK1 or 3, which did not result in
significant changes in CRTC2 phosphorylation and the amount of
adenovirus (scramble control) required for dual (SIK1&3)
knockdown itself affected glucose production (B30% reduction
in unstimulated cells; data not shown). Therefore, this approach
could not provide compelling evidence to conclude whether there
is a dominant SIK isoform or whether SIK isoforms play a
redundant role in the control of hepatic gluconeogenesis. As a
next step, it would be interesting to generate and analyze liver-
specific SIK1 or SIK3, and if viable, double (SIK1/3) or TKO
(SIK1/2/3) mouse models.
A key finding of this study is that the cAMP–PKA pathway and
SIKs appear to regulate CRTCs and gluconeogenesis at least
partially through distinct mechanisms. This notion is based on
the following: (1) Bt2-cAMP, but not the SIK inhibitor promoted
glucose production in LKB1-deficient hepatocytes (Fig. 7c),
suggesting that SIK activity is not required for cAMP regulation
of glucose production and, (2) co-incubation with HG-9-91-01
and glucagon resulted in an additive effect on glucose production.
In line with these findings, glucagon promotes mobilization of
Ca2þ through phosphorylation of IP3R (Ser1756), which in turn
activates calcineurin (also known as protein phosphatase 2B)
leading to dephosphorylation and nuclear translocation of
CRTCs, and a resultant activation of CREB-regulated gluco-
neogenic genes in hepatocytes19. A calcineurin inhibitor
(cyclosporin A) blocked glucagon-induced dephosphorylation of
CRTC2 in concert with gluconeogenic gene promoter activity19;
thus, it would be interesting to determine if HG-9-91-01-induced
glucose production is sensitive to cyclosporin A. In addition to
this mechanism it has also been proposed that glucagon increases
hepatic glucose production by regulating Ca2þ -CaMKII-
mediated FoxO1 nuclear localization26. Moreover, although
CRTC2 has been proposed as a key regulator for gluconeogenic
gene expression and glucose production, CRTC2 is dispensable in
glucagon-mediated glucose production27 and we also observed that
HG-9-91-01 stimulates glucose production in CRTC2-deficient
primary hepatocytes (Supplementary Fig. 11). All in all, the precise
signalling pathways that mediate glucagon-induced hepatic
gluconeogenesis are still not fully understood, but most likely
involve the key second messengers, cAMP and calcium ions, and
multiple downstream effectors such as kinases (for example, PKA,
CaMKII) and phosphatases (for example, calcineurin) with
subsequent regulation of multiple cytosolic PKA targets (for
example, 6-phosphofructo-2-kinase, IP3R) and transcription
factors/co-activators (for example, CRTCs, FoxOs, HNF-4a,
PGC-1a, histone acetylase/deacetylases) that directly or indirectly
regulate gluconeogenic gene expression1,10,19,24,26.
In summary, we provide evidence that SIK isoforms signifi-
cantly contribute to suppression of hepatic gluconeogenesis by
regulating downstream transcription factors/co-activators and
that glucagon (but not insulin) can regulate phosphorylation of
SIK2 (Fig. 9). However, glucagon can switch on the gluconeo-
genic gene programme through multiple distinct pathways
(possibly involving both SIK-independent and -dependent
pathways) whose precise mechanism is still under intensive
investigation.
Methods
Materials. Forskolin, MK-2206 and PI-103 were from Tocris (Avon, UK). Protein
G-Sepharose, glutathione-Sepharose and enhanced chemiluminescence reagents
were purchased from GE Healthcare (Piscataway, NJ, USA). [g32P]-labelled ATP
was from Perkin Elmer (MA, USA). Precision Plus protein markers and SsoFast
EvaGreen Supermix were from Bio-Rad (Hertfordshire, UK). Insulin-like growth
factor 1 (IGF-1) was from Cell Signaling Technology (Hertfordshire, UK). Protease
inhibitor cocktail tablets were purchased from Roche (Lewes, UK). Anti-HA-
agarose, anti-FLAG-agarose, collagenase (from clostridium histolyticum type IV,
Cat no. C5138), triiodothyronine, Bt2-cAMP and lactate were from Sigma-Aldrich
(Poole, UK). Infinity glucose assay kit was from Thermo Scientific (Essex, UK).
Insulin and glucagon were from Novo Nordisk (Sussex, UK). Cell culture media
and reagents including Dulbecco’s modified eagle medium (DMEM) and M199
with glutamax were from Life Technologies (Paisley, UK). All other chemicals
unless specified were obtained from Sigma-Aldrich.
DNA constructs. Human SIK1 (NM_173354), human SIK2 (XM_041314) and
human SIK3 sequences (XM_005271481.1) were cloned into pCMV5 vector using
standard molecular biology techniques. Site-directed mutagenesis technique
was used for generating all of the mutants that were used in this manuscript.
AdEasy expression system (Agilent technologies, Cheshire, UK) was used to
generate recombinant adenovirus for expression of the WT SIK2, SIK2
phosphorylation-site mutants (Ser/Thr to Ala) and SIK2 drug-resistant mutant
(T96Q) under the regulation of the pCMV promoter. Recombinant adenoviruses
were generated and titered according to the manufacturer’s instructions.
Antibodies. SIK2 (#6919), pSer473 Akt (#9271), pThr308 Akt (#9275), Akt2
(#2964), pSer133 CREB (#9198), CREB (#9197), p-Akt substrate (#9614), p-PKA
substrate (#9621), pSer157 VASP (#3111), pSer246 HDAC4 (#3443), IP3R (#1178),
pSer1756 IP3 receptor (#3760), AMPKa (#2532), pThr172 AMPK (#2535), ACC
(#3662), pSer79 ACC (#3661) and PEPCK (#6924) antibodies were obtained from
Cell Signaling Technology. CRTC2 (ST1099) and Tubulin (CP06) antibodies were
purchased from Calbiochem (Nottingham, UK). CRTC3 (Ab91654) and GAPDH
(Ab8245) antibodies were obtained from Abcam (Cambridge, UK), while anti-HA
(12013819001) antibody was purchased from Roche. Secondary antibodies were
obtained from Jackson ImmunoResearch (Suffolk, UK). Antibodies against SIK1,
SIK2 and SIK3 (ref. 12), pThr182 SIK1 (recognizes equivalent T-loop site of SIK2/
3; ref. 28) and pSer358 SIK2 (ref. 17) have been described previously. Antibodies
against full-length human VASP (S407B, first bleed) and GFP (residues 2–238,
S268B, first bleed) were generated in-house. Antibodies against pSer343 SIK2
(LKSHRSpSFPVEQR, residues 337–349 of human SIK2) and pSer484 SIK2
(GQRRHpTLSEVTNQ, residues 479–491 of human SIK2) were generated by
YenZym custom antibody production service (South San Francisco, CA, USA).
pSer577 SIK1 (recognizes equivalent pSer587 SIK2) was a gift from Dr Hiroshi
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Figure 9 | Schematic diagram showing LKB1–SIK pathway in the control
of hepatic gluconeogenesis. Activity status of SIKs influences
phosphorylation of transcription co-activators such as HDACs and CRTCs
their nuclear-cytoplasm shuttling and gluconeogenic gene expressions in
the liver.
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Takemori (National Institute of Biomedical Innovation, Osaka, Japan) and has
been described previously29. pSer33 PFKFB1 antibody has been described
previously10.
Protein sequence. Protein sequences for SIK1 (Homo sapiens, P57059), SIK2
(Homo sapiens, Q9H0K1) and CRTC2 (Homo sapiens, Q53ET0) were obtained
from the Swiss-Prot database while SIK3 sequence was obtained from NCBI
(XP_005271538.1).
Animals. Animal studies were approved by the University of Dundee and the Paris
Descartes University ethics committee (no. CEEA34.BV.157.12) and performed
under a UK Home Office project licence or a French authorization to experiment
on vertebrates (no.75–886) in accordance with the European guidelines or the
University of Pennsylvania IACUC in accordance with the National Institute of
Health guidelines. Generation of the Akt2 / mice has been described
previously18. Liver-specific AMPKa1/a2 KO mice have been described previously4.
SIK2 (Snf1lk2) targeting construct was generated from PCR products amplified
from the DNA of 129/Sv ES cells by the pfx polymerase (Invitrogen). The 50 and 30
homology arms, both 3.4 kb in length, were inserted on either side of a PGK
promoter-driven hygromycin selection cassette flanked by FLP Recognition Target
(FRT) sites, into the pL3-FRT-Hygro vector. A 1.1-kb fragment of genomic DNA
bearing exon 5, encoding partially the SIK2 catalytic domain including the
phosphorylation-site Thr175 within the activation loop (corresponding to amino
acids 160–201), flanked by loxP sites, was introduced between the hygromycin
resistance cassette and the 30 homology arm (Fig. 2a). Exponentially growing
129/SV CK35 embryonic stem cells30 were electroporated with the linearized target
construct DNA and selected on plates containing hygromycin. The targeted clones
were identified by PCR across both homology arms, with confirmation by Southern
blot analysis. Cell populations expanded from the targeted clones were injected into
C57BL/6 eight-cell embryos with a laser-assisted micromanipulation system, and
animals displaying germline transmission were mated with C57BL/6J mice. The
hygromycin resistance cassette flanked by FRT sites were excised by crossing
SIK2lox/þ mice with flippase (FLP)-expressing mice31. The resulting heterozygous
offspring were backcrossed to at least four generations into the C57BL/6J
background. Liver disruption of exon 5 flanked by loxP sites was achieved by
crossing SIK2-floxed mice with Alfp–Cre transgenic mice32 to generate SIK2lox/lox
(control) and SIK2lox/lox–Alfp–Cre (liver KO) mice. Routine genotyping was
carried out by multiplex PCR on tail DNA with the P1 (50-gtagtttacattagcacattggt
gcctc-30), P2 (50-cctagaatgcactctgcaaacactggacac-30) and P3 (50-tctacatggagggtgtcgca
gagctccatg-30) primers, to yield amplification products of 391 bp (WT allele) and
487 bp (floxed allele) with P1/P2 and 708 bp (KO allele) with P1/P3. Liver TKO of
AMPKa1, AMPKa2 and SIK2 was achieved by crossing SIK2lox/lox–Alfp–Cre mice
with AMPKa1lox/lox, a2lox/lox mice to generate AMPKa1lox/lox, a2lox/lox, SIK2lox/lox
(control) and AMPKa1lox/lox, a2lox/lox, SIK2lox/lox–Alfp–Cre (liver TKO) mice.
Ten-week-old male mice were used in all experiments.
Liver-specific LKB1 KO mice were generated by crossing LKB1lox/lox mice
(kindly provided by Ronald DePinho, Harvard University)33 with tamoxifen-
inducible albumin–Cre–ERT2 mice (kindly provided by Daniel Metzger, IGBMC,
France)34. Ten-week-old male LKB1lox/lox–Alb–Cre–ERT2 mice were treated either
with vehicle containing sunflower oil and ethanol 10% (control) or tamoxifen
(Sigma) at 1mg per mouse injected intraperitoneally in a final volume of 100 ml for
5 consecutive days. Mice were studied or used for primary hepatocyte isolation 3
weeks after the start of tamoxifen administration. Male C57BL/6 mice were
obtained from Harlan (UK) and 8–12-week-old male mice were used for
experiments. All mice were maintained on a standard chow diet (or high-
carbohydrate diet described in Supplementary section) and 12/12 h light/dark
in a barrier facility.
Fasting/refeeding and oral glucose tolerance test. For the fasting–refeeding
experiment, mice were either fasted for 18 h or fasted for 24 h then refed a
high-carbohydrate diet (Harlan TD.08247) for 12 h. Oral glucose tolerance test
was performed on mice fasted for 16 h as previously described4. Blood
glucose levels were determined at 0, 20, 40, 60, 90 and 120min after oral
administration of glucose (3 g kg 1 body weight) using a glucometer (Roche
Diagnostics).
Primary hepatocyte culture and glucose production measurement. Primary
hepatocytes were isolated from fed 10-week-old male mice by a modified version of
the collagenase method35 Hepatocyte preparations that displayed a cell viability
Z90% were used for experiments. Isolated hepatocytes were plated in 12-well
plates at a density of 1.25 105 per well in the plating medium (M199 with
glutamax supplemented with 100Uml 1 penicillin, 0.1mgml 1 streptomycin,
0.1% bovine serum albumin (BSA), 10% (v/v) foetal bovine serum, 10 nM insulin,
200 nM triiodothyronine, 500 nM dexamethasone) for 4–6 h and then incubated
with overnight medium (M199 with glutamax supplemented with 100Uml 1
penicillin, 0.1mgml 1 streptomycin and 100 nM dexamethasone). The next
morning, cells were washed once with 1ml of PBS and 750 ml of the assay medium
(containing DMEM without glucose, 100 Uml 1 penicillin and 0.1mgml 1
streptomycin, 100 nM dexamethasone, 1mM sodium pyruvate and 10mM lactate,
pH 7.4) was added per well. The cells were stimulated with the respective
compounds or hormones for the indicated time described in the figure legends and
glucose production (glucose in the medium) was measured using the hexokinase/
glucose-6-phosphate dehydrogenase method4,36.
Preparation and infection of adenovirus. Generation of recombinant adenovirus
carrying genes of our interest (GFP and GFP- or HA-tagged SIK2 wild type and
mutants) was carried out either using AdEasy system (Agilent Technologies,
Berkshire, UK) according to manufacturer’s protocol and the adenovirus was
purified using caesium chloride banding according to the protocol described by
Luo et al.37 in house or generated and purified by Vector Biolabs (CA, USA).
Adenoviruses were added to the cells at a defined multiplicity of infection (MOI).
One MOI equals one infectious viral particle per cell. For overexpression studies in
primary hepatocytes, the cells were infected with the indicated MOI for 16 h prior
to cell lysis.
Immunoprecipitation of HA–SIK2 for mass spectrometry. Primary mouse
hepatocytes were infected with adenoviruses encoding WT or mutant SIK2 at 1:25
MOI for 16 h. These cells were left untreated or stimulated with 10 nM insulin or
100 nM glucagon for 10min and lysed. HA–SIK2 was immunoprecipitated from
5mg of clarified lysates with 30ml of anti-HA-agarose beads. The washed beads
were heated with 1 NuPAGE LDS sample buffer (Invitrogen) and 10mM DTT
for 5min at 70 C. Samples were further incubated with 50mM iodoacetamide for
30min to alkylate cysteine residues and electrophoresed on NuPAGE 4–12%
Bis-Tris gels (Invitrogen). The gels were colloidal coomassie stained and HA–SIK2
bands were excised and processed as below.
Sample preparation for mass spectrometry. Samples were prepared in a laminar
flow hood to reduce contamination. The gel pieces were cut and washed for 10min
with 500 ml of water, 50% acetonitrile/water, 0.1M ammonium bicarbonate
(NH4HCO3) and 50% acetonitrile/50mM NH4HCO3. Washes were carried out on
a vibrax-shaking platform and all liquid was removed between washes. The final
step was repeated until the gel pieces were colourless. Acetonitrile (0.3ml) was
added to these gel pieces and removed after 15min. The gel pieces were dried in a
centrifugal-evaporator (Speed-Vac). The protein in the dried gel pieces was
digested in 30ml of 25mM triethylammonium bicarbonate containing 5 mgml 1 of
trypsin at 30 C overnight on a shaking platform. Subsequently, an equivalent
volume of acetonitrile was added for 15min. The supernatant was collected in a
clean tube and dried using a Speed-Vac. Meanwhile 100ml of 50% acetonitrile/2.5%
formic acid was added to the gel pieces and incubated for 15min. The supernatant
was combined with the first dried extract and dried in a
Speed-Vac and stored at  20 C.
Phosphorylation-site identification by mass spectrometry. Phospho-peptides
and their approximate relative abundances were initially identified by LC-MS-MS
mass spectrometry on an Applied Biosystems 4000 QTrap coupled to a Dionex
Ultimate 3000 liquid chromatography system. The MS was set up to use a
precursor ion scan of m/z 79 in negative ion mode followed by an ion trap
high resolution and a high sensitivity MS-MS scan in positive mode38. QTrap
precursor ion analysis was used to allow simple observation of variations in
phosphopeptide intensity from one treatment to another. Data was analysesd using
Analyst software (ABSciex). Phospho-peptides were also further analysed by
LC-MS-MS on a Thermo LTQ-Orbitrap Classic equipped with a nanoelectrospray
ion source (Proxeon Biosystems) and coupled to a Proxeon EASY-nLC system.
Multi-Stage-Activation was used to provide an MS3 scan of any parent ions
showing a neutral loss of 48.9885, 32.6570, 24.4942, allowing for 2þ , 3þ and 4þ
charge states, respectively. The resulting MS3 scan was automatically combined
with the relevant MS2 scan prior to data analysis. Results were searched against an
in-house database containing the SIK sequences using the Mascot algorithm
(www.matrixscience.com) to identify peptides. Phosphorylation sites on the
peptides were also analyzed with Xcalibur software and Proteome Discoverer
(Thermo Scientific).
Quantitative PCR analysis. Total RNA from primary hepatocytes and mouse
liver tissue was extracted using Trizol (Invitrogen), and single-strand com-
plementary DNA was synthesized from 5 mg of total RNA with random hexamer
primers (Applied Biosystems) and Superscript II (Invitrogen). Real-time reverse
transcription–PCRs were carried out in a final volume of 20 ml containing 125 ng of
reverse-transcribed total RNA, 500 nM of primers and 10 ml of 2 PCR mix
containing Sybr Green (Roche). The reactions were performed in 96-well plates in
a LightCycler 480 instrument (Roche) with 40 cycles. We determined the relative
amounts of the mRNAs studied by means of the second-derivative maximum
method, with LightCycler 480 analysis software and 18S RNA as the invariant
control for all studies. The sense and antisense PCR primers used, respectively,
were as follows: for Ppargc-1a, 50-ATACCGCAAAGAGCACGAGAAG-30 ,
50-CTCAAGAGCAGCGAAAGCGTCACAG-30 ; for Pck1, 50-GTGCTGGAGTGG
ATGTTCGG-30 , 50-CTGGCTGATTCTCTGTTTCAGG-30; for G6pc, 50-ACTGTG
GGCATCAATCTCCTC-30 , 50-CGGGACAGACAGACGTTCAGC-30 ; for 18S,
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50-GTAACCCGTTGAACCCCATT-30 , 50-CCATCCAATCGGTAGTAGCG-30 ; for
Fasn, 50-AGCGGCCATTTCCATTGCCC-30, 50-CCATGCCCAGAGGGTGG
TTG-30 ; for Srebp-1c, 50-GGAGCCATGGATTGCACATT-30 , 50-GCTTCCAGAGA
GGAGGCCAG-30.
General cell culture. HEK293 and Ad-293 cells were cultured in DMEM
supplemented with 10% (v/v) foetal bovine serum, 2mM L-glutamine, 100Uml 1
penicillin and 0.1mgml 1 streptomycin. They were maintained in T75 flasks at
50–80% confluence for a maximum of 20 passages. Cells were split at 70–80%
confluence and plated in a new dish or flask after an appropriate dilution. Cells
were serum starved overnight before stimulating with hormones, growth factors or
kinase inhibitors.
Cell lysis. Medium was aspirated and cells were rinsed once with ice-cold PBS.
Cells were subsequently lysed on ice using ice-cold lysis buffer (50mM
Tris-HCl, pH 7.5, 1mM EGTA, 1mM EDTA, 1% (w/v) Triton X-100, 1mM
Na3VO4, 50mM NaF, 5mM sodium pyrophosphate, 0.27M sucrose, 0.1% (v/v)
2-mercaptoethanol and ‘complete’ protease inhibitor cocktail). Whole-cell lysate
was cleared of insoluble particles by centrifugation at 4 C, 13,000g for 10min. The
supernatant was removed and stored at  80 C.
Preparation of tissue lysates. Frozen liver samples were homogenized using a
rotor-stator homogenizer (Polytron, Kinematica AG) in 20 volumes of ice-cold
lysis buffer, clarified for 10min at 13,000g at 4 C and protein concentration
determined using Bradford reagent (Pierce) with BSA as standard. Lysates were
stored at  80 C.
Immunoprecipitation of endogenous SIK2 protein. SIK2 antibody or
pre-immune immunoglobulin G (2–3 mg; as a control) was incubated with 5 ml of
protein G-Sepharose for 1 h at 4 C on an orbital shaker. This mixture was then
added to 0.5–2mg of cell/tissue extracts and further incubated at 4 C for 1 h prior
to isolation by centrifugation. The resultant precipitates were washed and used for
immunoblotting or kinase assays as follows (and also shown previously17,39).
Immunobloting. Cell or tissue lysates (20–40 mg) were denatured in Laemmli
buffer, separated by SDS–polyacrylamide gel electrophoresis and transferred to
nitrocellulose. Membranes were blocked in 50mM Tris-HCl pH 7.6, 137mM NaCl
and 0.1% (v/v) Tween-20 containing 10% (w/v) skimmed milk or 5% (w/v) BSA
for 1 h at room temperature and incubated overnight at 4 C with the indicated
primary antibodies. Detection was performed using horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence reagent.
Uncropped images of immunoblots are shown in Supplementary Fig. 12.
SIK activity assays. SIK isoforms were immunoprecipitated from liver tissue/
hepatocyte extracts (0.5–2mg). SIK activity assay was performed in a final volume
of 50ml containing 15ml of protein kinase (immune purified/precipitated) and 35 ml
of reaction mix. The reaction mix contained 200mM of Sakamoto-tide peptide
(ALNRTSSDSALHRRR), 50mM HEPES, 1mM EGTA, 10mM magnesium acetate
and 0.1mM [g32P]-labelled ATP. Control reactions either lacked purified kinase or
contained pre-immune immunoglobulin G-coupled beads. Phosphorylation reac-
tions were initiated by adding reaction mix to the protein kinase and incubating on
a thermomixer at 30 C for 20min. These reactions were terminated by spotting
40ml of mixture onto P81 phosphocellulose paper and immersing them in 75mM
orthophosphoric acid. P81 papers were washed three times for 10min with 75mM
orthophosphoric acid and finally in acetone for 5min. P81 papers were air-dried
and the incorporation of 32P into peptide substrate was determined by Cherenkov
counting. Results were expressed in mUmg1 protein where 1mU equals 1 pmol
of phosphate incorporation into a substrate in 1min at 30 C (refs 17,39).
Immunofluorescence. Primary mouse hepatocytes were fixed on glass cover slips
with 3.7% paraformaldehyde after the treatment indicated in figure legends.
Cells were washed three times with PBS containing 5% (w/v) BSA followed by
incubation with 0.1% NP-40 in PBS for 5min. Subsequently, cells were blocked
with PBS containing 5% (w/v) BSA for 20min and incubated with anti-rabbit SIK2
antibody (Cell Signaling, #6924) or anti-rabbit CRTC2 antibody (Calbiochem, Cat
no. ST1099) at a dilution of 1:500 for 1 h at 37 C. Excess antibodies were removed
by washing the cells three times with PBS containing 5% (w/v) BSA. This was
followed by a 30min incubation with secondary antibody (Alexa Fluor 488).
Subsequently the cells were further washed three times with PBS containing 5%
(w/v) BSA before mounting the cover slips on a glass slide with mounting media
containing 40 ,6-diamidino-2-phenylindole. Cells were later analyzed with a Nikon
Eclipse Ti fluorescent microscope and images were captured using Nikon NIS
Elements BR 3.1 software.
Statistics. Data are expressed as mean±standard deviation or standard error.
Statistical analysis was performed using Student’s t-test or one-way or two-way
analysis of variance using Tukey’s or Dunnet’s test for multiple comparisons where
appropriate. Differences between groups were considered statistically significant at
Po0.05.
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